Emmaus Life Sciences, Inc. (EMMA) stock
Close on Oct 19, 2026Market cap $6.03MP/E –Yield –
Emmaus Life Sciences, Inc. reported revenue of $15.53M for the twelve months to Jun 30, 2026. Free cash flow was -$12.00K. At the latest close the market valued the company at $6.03M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $6.03M
- P/E ratio
- –
- Price to sales
- 0.39
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -0.20%
Fundamentals
- Revenue
- $15.53M
- Net income
- -$6.02M
- EPS, diluted
- -$0.09
- Free cash flow
- -$12.00K
- Book value per share
- -$0.55
- Diluted shares
- 121M
Trading
- Next earnings
- Nov 13, 2026 (estimated, during market hours)
- Previous close
- $0.06
- Open
- $0.04
- Day's range
- $0.04 – $0.06
- Volume
- 19,640
- Average volume (20 days)
- 19,620
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | EMMA | S&P 500 | Difference | EMMA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.4% | +0.6% | −27.0 pts | ||
| 3 months | +338.6% | +3.4% | +335.2 pts | ||
| Year to date | +284.6% | +13.3% | +271.3 pts | ||
| 1 year | +320.2% | +16.6% | +303.6 pts | ||
| 3 years | -64.2% | +86.4% | −150.6 pts | -29.0% | +23.1% |
| 5 years | -96.7% | +81.9% | −178.5 pts | -49.4% | +12.7% |
| 10 years | -99.9% | +318.9% | −418.8 pts | -50.2% | +15.4% |
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Emmaus Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Results
- Results
About Emmaus Life Sciences
Pharmaceutical Preparations
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of treatments and therapies primarily involving pharmaceutical-grade L-glutamine. Its principal commercial product is Endari, which is marketed for patients with sickle cell disease. The company organizes its operations and product sales across domestic and international channels, serving healthcare distributors and medical providers across different markets.
Company profile, executives and historyEmmaus Life Sciences stock: common questions
What is Emmaus Life Sciences's stock price?
EMMA closed at $0.05 on Oct 19, 2026, down 14.38% on the day.
What is Emmaus Life Sciences's market cap?
Emmaus Life Sciences was worth $6.03M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is EMMA's P/E ratio?
Emmaus Life Sciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.09), so it has no meaningful P/E ratio.
How much revenue does Emmaus Life Sciences make?
Emmaus Life Sciences reported revenue of $15.53M for the twelve months to Jun 30, 2026.
Does Emmaus Life Sciences pay a dividend?
No. Emmaus Life Sciences has not paid a cash dividend over the last twelve months.
When does Emmaus Life Sciences report earnings next?
Emmaus Life Sciences is expected to report Q3 FY2026 results on Nov 13, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has EMMA stock performed over the past year?
Including dividends, EMMA returned +320.2% over the past year, against +16.6% for the S&P 500.
Who are Emmaus Life Sciences's competitors?
Companies most similar to Emmaus Life Sciences by business, industry and size include EVFM, PRQR, JAGX, CASIF, CELU.
See a number that looks wrong?